Transcutaneous oxygen monitoring. Its use in the treatment of outpatients with congenital heart disease.
To validate transcutaneous Po2 (TcPo2) monitoring for outpatient use in cyanotic congenital heart disease (CCHD), TcPo2 was compared with simultaneous arterial Po2 at cardiac catheterization and with arterial Po2 obtained by puncture. Over a 40-month period, 1,493 outpatient TcPo2 determinations were made in 461 patients to diagnose the presence or absence of hypoxemia in newly referred patients and to help assess oxygen delivery in patients with known CCHD. Clinical decisions regarding the need for further diagnostic study and the adequacy of oxygen delivery were made based on these determinations.